U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C22H32N2O6
Molecular Weight 420.5001
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HEXOPRENALINE

SMILES

C(CCCNCC(c1ccc(c(c1)O)O)O)CCNCC(c2ccc(c(c2)O)O)O

InChI

InChIKey=OXLZNBCNGJWPRV-UHFFFAOYSA-N
InChI=1S/C22H32N2O6/c25-17-7-5-15(11-19(17)27)21(29)13-23-9-3-1-2-4-10-24-14-22(30)16-6-8-18(26)20(28)12-16/h5-8,11-12,21-30H,1-4,9-10,13-14H2

HIDE SMILES / InChI

Molecular Formula C22H32N2O6
Molecular Weight 420.5001
Charge 0
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including, http://home.intekom.com/pharm/intramed/ipradinf.html

Hexoprenaline is a selective beta2-adrenoreceptor agonist indicated for use in the treatment of bronchospasm associated with obstructive airways diseases, including asthma, bronchitis and emphysema. In many countries the drug is used as tocolytic agent (under the trade name gynipral).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Preventing
GYNIPRAL

Approved Use

Gynipral prevents threatened abortion with premature labour.
PubMed

PubMed

TitleDatePubMed
[Tocolysis with hexoprenalin and salbutamol in a clinical comparison].
1983 Mar
A comparison of the relative toxicities of beta-sympathomimetic tocolytic agents.
1985 Oct
[Comparison of the cost of treatment of premature labor with atosiban or beta-sympathomimetics from the perspective of the health care payer--a pharmacoeconomic model].
2004 Mar
Betamimetics for inhibiting preterm labour.
2004 Oct 18
Beta 2-agonist treatment enhances uterine oxytocin receptor mRNA expression in pregnant rats.
2004 Sep
Arg16 homozygosity of the beta2-adrenergic receptor improves the outcome after beta2-agonist tocolysis for preterm labor.
2005 Dec
Circulatory corticotropin-releasing hormone mRNA concentrations are increased in women with preterm delivery but not in those who respond to tocolytic treatment.
2005 Mar
Flow injection potentiometric assay of hexoprenaline in its pure state, pharmaceutical preparations, and biological samples.
2008
Treatment of pregnant women with a betamimetic and verapamil increases the micronuclei frequency in umbilical cord blood lymphocytes.
2008 Aug
Atosiban versus betamimetics in the treatment of preterm labour in Germany: an economic evaluation.
2009 Jun 19
Management of foetal asphyxia by intrauterine foetal resuscitation.
2010 Sep
Dependence of the lymphocyte proliferative response on the endogenous cortisol level and sensitivity to β-adrenergic regulation in vitro in the early period of penetrating eye injury.
2010 Sep-Oct

Sample Use Guides

In Vivo Use Guide
Sources: www.ncbi.nlm.nih.gov/pubmed/195789
Hexoprenaline can be given by metered aerosol in doses of 200 to 400μg, up to 5 times daily (in asthma), or as an infusion of 0,30 ug and 0,45 ug per minute or as 1-2 tablets q.i.d (0.5 mg per tablet) (maintenance dose in premature labour).
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 06:13:27 UTC 2021
Edited
by admin
on Sat Jun 26 06:13:27 UTC 2021
Record UNII
G9L6B3W684
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HEXOPRENALINE
INN   MI   WHO-DD  
INN  
Official Name English
HEXOPRENALINE [WHO-DD]
Common Name English
ST-1512
Code English
HEXOPRENALINE [MI]
Common Name English
HEXOPRENALINE [INN]
Common Name English
ST1512
Code English
IPRADOL
Brand Name English
1,2-BENZENEDIOL, 4,4'-(1,6-HEXANEDIYLBIS(IMINO(1-HYDROXY-2,1-ETHANEDIYL)))BIS-
Systematic Name English
Classification Tree Code System Code
WHO-ATC R03AC06
Created by admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
WHO-ATC R03CC05
Created by admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
WHO-VATC QR03CC05
Created by admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
WHO-VATC QR03AC06
Created by admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
Code System Code Type Description
INN
2650
Created by admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
PRIMARY
EPA CompTox
3215-70-1
Created by admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
PRIMARY
WIKIPEDIA
HEXOPRENALINE
Created by admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
PRIMARY
ChEMBL
CHEMBL1589896
Created by admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
PRIMARY
RXCUI
5307
Created by admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
PRIMARY RxNorm
FDA UNII
G9L6B3W684
Created by admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
PRIMARY
DRUG BANK
DB08957
Created by admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
PRIMARY
MESH
D006594
Created by admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
PRIMARY
NCI_THESAURUS
C170044
Created by admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
PRIMARY
CAS
3215-70-1
Created by admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
PRIMARY
PUBCHEM
3609
Created by admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
PRIMARY
MERCK INDEX
M6013
Created by admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
PRIMARY Merck Index
EVMPD
SUB08041MIG
Created by admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
PRIMARY
DRUG CENTRAL
1372
Created by admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
SHORT-ACTING
Related Record Type Details
ACTIVE MOIETY